
Sign up to save your podcasts
Or
We’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology!
In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data.
Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s.
Our thanks and appreciation to our guest KOL hepatologists, thought leaders in NASH pharma and moderator!
Guests
Prof. Stephen Harrison (Pinnacle Clinical Research)
Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital)
Dr. Judith Ertle (Boehringer Ingelheim)
Dr. Karin Conde-Knape (Novo Nordisk)
Absent with Apologies - Ms. Kitty Yale (Akero Therapeutics)
Moderator
Dr. Nikolai Naoumov (Novartis)
We’re very happy to bring you Part 4 that will wrap up the Special Episode podcast of Dialogues on AI Digital Pathology!
In this Part 4 podcast, our guests – KOL Hepatologists and Pharma Thought Leaders in NASH – continue their discussions in response to questions by Pharma companies and clinical investigators. Find out their views on how AI Digital Pathology (AI-DP) can effectively impact NASH drug development, preclinical studies and clinical practice with granular histopathological data.
Please click here to view the Key Takeaways for Part 4 or go to https://tinyurl.com/b4ttvb4s.
Our thanks and appreciation to our guest KOL hepatologists, thought leaders in NASH pharma and moderator!
Guests
Prof. Stephen Harrison (Pinnacle Clinical Research)
Prof. Vlad Ratziu (Sorbonne University Pitié-Salpêtrière Hospital)
Dr. Judith Ertle (Boehringer Ingelheim)
Dr. Karin Conde-Knape (Novo Nordisk)
Absent with Apologies - Ms. Kitty Yale (Akero Therapeutics)
Moderator
Dr. Nikolai Naoumov (Novartis)